#Ireland #Dublin #West Pharmaceutical #Dublin Facility #Injectable Solutions

West Pharmaceutical Services Expands Its Dublin Facility

West Pharmaceutical Services, Inc., a leading name in injectable drug administration, has made a significant stride by expanding its facility located in Damastown, Dublin. The new building, which spans 165,000 square feet, aims to bolster the company's contract services and address the surging global demand for high-volume injectable therapies, especially for conditions like diabetes and obesity.

The expansion represents a vital step for West, further solidifying its commitment to providing high-quality solutions in drug delivery systems. The building was officially inaugurated with attendance from prominent figures including Eric Green, the Chief Executive Officer of West; Aileen Ruff-Patry, President of Contract Manufacturing at West; as well as Jack Chambers, Ireland's Minister for Public Expenditure and other local dignitaries.

In addressing the gathering, Aileen Ruff-Patry expressed pride in the expansion, emphasizing West's dedication to supporting the customer base in delivering reliable and secure drug delivery solutions. She noted that this facility would enhance West’s capacity to manage drug handling for high-volume injectable therapies, such as next-generation GLP-1 treatments. This expansion places West in a robust position as a vital partner in ensuring patients have access to essential medicines.

As the need for complex injectable systems surges, the significance of integrated development and commercialization services cannot be overstated. The new Damastown facility not only amplifies West's capabilities but also enhances its services to include advanced automation alongside expanded drug-handling options. This alignment with commercial scale reflects West's commitment to staying ahead of industry demands.

This project is part of West Vantage™, the comprehensive contract services division of the company. West Vantage™ offers a holistic approach to drug manufacturing that covers every aspect of production, from initial product conceptualization through development and assembly to packaging, validation, analytical testing, and regulatory compliance. By providing a seamless transition from concept to market, West empowers its pharmaceutical and biotech partners, facilitating quicker access to market for life-saving therapies.

West Pharmaceutical Services is a notable supplier of innovative, high-quality injectable solutions and services. With more than 10,000 employees across 50 global locations, including 25 dedicated manufacturing facilities, West plays a crucial role in ensuring patients receive safe and effective medicines. In the fiscal year 2025, the company's impressive net sales reached $3.07 billion, showcasing its significant impact in the healthcare sector. As a publicly traded entity on the New York Stock Exchange under the ticker symbol WST, West continues to expand its footprint in the industry, being a part of the Standard & Poor's 500 index.

For more detailed information about the new facility or West's services, you can visit www.westpharma.com.